Anika Therapeutics, Inc. (ANIK) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, Anika Therapeutics reported revenue of $112.8M, down 5.9% from $119.9M the year before. Net income was -$10.9M (a -9.6% net margin), or -$0.76 per diluted share. Gross margin was 56.6% and operating margin was -9.8%. Operating activities generated $11.2M of cash, leaving $4.4M of free cash flow. At fiscal year end, Anika Therapeutics held $190.3M in total assets against $46.8M in total liabilities, including $57.5M of cash and equivalents.
Open the full interactive Anika Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Anika Therapeutics Key Stats
| Share Price | $20.53 |
|---|---|
| Market Cap | $281.6M |
| Revenue YoY Growth | -5.9% |
| 52-Week Range | $9.09 – $22.03 |
| Shares Outstanding | 13.3 million (basic, 2026 Q2) |
Anika Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $130.5M | $147.8M | $156.2M | $166.7M | $119.9M | $112.8M |
| Cost of Goods Sold | $61.4M | $64.9M | $62.7M | $63.6M | $43.9M | $49.0M |
| Gross Profit | $69.0M | $82.9M | $93.6M | $103.1M | $76.0M | $63.8M |
| Operating Income | -$28.3M | $2.6M | -$19.4M | -$87.6M | -$5.1M | -$11.1M |
| Pre-Tax Income | -$28.6M | $2.4M | -$18.7M | -$85.3M | -$2.8M | -$9.3M |
| Income Tax | -$4.6M | -$1.7M | -$3.9M | -$2.7M | $6.1M | $672,000 |
| Net Income | -$24.0M | $4.1M | -$14.9M | -$82.7M | -$56.4M | -$10.9M |
| Diluted EPS | -$1.69 | $0.28 | -$1.02 | -$5.64 | -$3.83 | -$0.76 |
Anika Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $27.8M | $30.6M | $29.6M | $32.6M |
| Net Income | -$2.3M | $292,000 | -$5.1M | $3.3M |
| Diluted EPS | -$0.16 | $0.02 | -$0.37 | $0.24 |
Anika Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $95.8M | $94.4M | $86.3M | $72.9M | $55.6M | $57.5M |
| Current Assets | $177.4M | $168.5M | $169.5M | $163.3M | $113.7M | $103.4M |
| Total Assets | $365.6M | $347.5M | $349.1M | $270.6M | $202.7M | $190.3M |
| Current Liabilities | $36.9M | $29.8M | $27.9M | $31.1M | $23.3M | $21.9M |
| Total Liabilities | $93.2M | $60.5M | $63.6M | $58.4M | $48.8M | $46.8M |
| Shareholders' Equity | $272.4M | $287.1M | $285.6M | $212.3M | $154.0M | $143.5M |
Anika Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $13.1M | $8.4M | $4.4M | -$1.8M | $5.4M | $11.2M |
| Cash From Investing | -$71.3M | -$3.1M | -$7.5M | -$5.4M | -$8.3M | -$401,000 |
| Cash From Financing | -$3.8M | -$6.8M | -$4.9M | -$6.3M | -$12.7M | -$10.6M |
| Free Cash Flow | $11.4M | $3.3M | -$3.1M | -$7.2M | -$2.3M | $4.4M |
Figures from Anika Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Anika Therapeutics financials page for every line item.
Anika Therapeutics Company Profile
| Ticker | ANIK |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Bedford, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer |
| SEC CIK | 0000898437 |
Frequently Asked Questions
What was Anika Therapeutics' revenue in fiscal 2025?
Anika Therapeutics (ANIK) reported revenue of $112.8M for fiscal 2025.
What is Anika Therapeutics' annual revenue history?
Anika Therapeutics' annual revenue by fiscal year: 2020: $130.5M; 2021: $147.8M; 2022: $156.2M; 2023: $166.7M; 2024: $119.9M; 2025: $112.8M.
What was Anika Therapeutics' net income in fiscal 2025?
Anika Therapeutics reported net income of -$10.9M for fiscal 2025.
What was Anika Therapeutics' earnings per share (EPS) in fiscal 2025?
Anika Therapeutics' diluted EPS was -$0.76 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Anika Therapeutics generate in fiscal 2025?
Anika Therapeutics generated $4.4M of free cash flow in fiscal 2025.
What was Anika Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Anika Therapeutics reported revenue of $32.6M.
How many shares of Anika Therapeutics are outstanding?
Anika Therapeutics reported a weighted average of 13.3 million basic shares outstanding in 2026 Q2.
What is Anika Therapeutics' market cap?
Based on its latest closing price, Anika Therapeutics (ANIK) has a market capitalization of about $281.6M.
When does Anika Therapeutics' fiscal year end?
Anika Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Anika Therapeutics headquartered?
Anika Therapeutics lists its business address in Bedford, Massachusetts in its SEC filings.
Anika Therapeutics Competitors & Similar Companies
See all 109 Surgical & Medical Instruments & Apparatus companies →